合成了一系列新的6-取代的2-氨基苯并噻唑衍生物,并在体外筛选为潜在的抗菌剂。几乎所有化合物均显示出抗真菌活性。特别是,根据分子模型研究设计的化合物1n,o是该系列中最好的化合物,对白色念珠菌,副念珠菌和热带念珠菌的MIC值为4-8μg/ mL 。两种化合物均未显示出对人THP-1细胞的任何细胞毒性作用。
合成了一系列新的6-取代的2-氨基苯并噻唑衍生物,并在体外筛选为潜在的抗菌剂。几乎所有化合物均显示出抗真菌活性。特别是,根据分子模型研究设计的化合物1n,o是该系列中最好的化合物,对白色念珠菌,副念珠菌和热带念珠菌的MIC值为4-8μg/ mL 。两种化合物均未显示出对人THP-1细胞的任何细胞毒性作用。
[EN] METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY<br/>[FR] PROCEDES ET COMPOSITIONS SERVANT A MODULER L'ACTIVITE DU RECEPTEUR DE LA SPHINGOSINE-1-PHOSPHATE (S1P)
申请人:PRAECIS PHARM INC
公开号:WO2006020951A1
公开(公告)日:2006-02-23
The present invention relates to compounds which modulate the activity of the SI P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1 P1 receptor, and pharmaceutical compositions comprising these compounds.
Dehydroxylation of alcohols for nucleophilic substitution
作者:Jia Chen、Jin-Hong Lin、Ji-Chang Xiao
DOI:10.1039/c8cc03856b
日期:——
The Ph3P/ICH2CH2I system-promoted dehydroxylative substitution of alcohols was achieved to construct C–O, C–N, C–S and C–X (X = Cl, Br, and I) bonds. Compared with the previous approaches such as the Appel reaction and Mitsunobu reaction, this protocol offers some practical advantages such as safe operation and a convenient amination process.
通过Ph 3 P / ICH 2 CH 2 I系统促进的醇的脱羟基取代反应,可构建C–O,C–N,CS–S和C–X(X = Cl,Br和I)键。与之前的方法(如Appel反应和Mitsunobu反应)相比,该方案具有一些实用的优点,例如操作安全和便捷的胺化过程。
Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
申请人:Saha K. Ashis
公开号:US20060135786A1
公开(公告)日:2006-06-22
The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprising these compounds.
Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity
申请人:Saha K. Ashis
公开号:US20080064662A1
公开(公告)日:2008-03-13
The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprising these compounds.